Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function-Reference-Cited by-同舟云学术

Risk of polymyxin B-induced acute kidney injury with a non adjusted dose versus adjusted dose based on renal function

Published:2022-07 Issue:4 Volume:19 Page:307-314
ISSN:1741-0541
Container-title:Personalized Medicine
language:en
Short-container-title:Personalized Medicine

Author:

Zheng Guanhao¹²,Cai Jiaqi³,Zhou Shenghui⁴,Du Ning⁵,Bai Hao⁶,He Juan¹^ORCID,Bian Xiaolan¹⁷

Affiliation:

1. Department of Pharmacy, Ruijin Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, 200000, China

2. Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200000, China

3. Department of Clinical Laboratory, Kunshan Hospital Affiliated to Nanjing University of Chinese Medicine, Kunshan, 215300, China

4. Department of Pharmacy, Baiyin Central Hospital, Baiyin, 730900, China

5. Department of Pharmacy, Qiqihar First Hospital, Qiqihar, 161000, China

6. Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, 400000, China

7. Department of Pharmacy, Luwan Branch of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200000, China

Abstract

Aim: To observe the difference in the risk of polymyxin B (PMB)-induced acute kidney injury (AKI) with or without dose adjustment based on the patients renal function. Materials & methods: This retrospective cohort analysis was carried out in 115 patients treated with PMB from November 2018 to October 2019. Results: No significant difference in the incidence of AKI as well as secondary outcomes was observed between these two groups (47.5 vs 37.14%; p = 0.304). Conclusion: Dosing adjustment based on renal function does not significantly lower the risk of PMB-induced AKI. A non adjusted dosing strategy for PMB is recommended in patients exhibiting various levels of renal impairment.

Funder

Shanghai ‘Rising Stars of Medical Talent’ Youth Development Program-Youth Medical Talents-Clinical Pharmacist Program

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/pme-2021-0003

Reference46 articles.

1. ‘Aerosporin’, an Antibiotic Produced by Bacillus aerosporus Greer

2. Paenibacillus polymyxa PKB1 Produces Variants of Polymyxin B-Type Antibiotics

3. Polymyxin B Nephrotoxicity: From Organ to Cell Damage

4. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis